113 related articles for article (PubMed ID: 14680454)
1. The potential of activation of somatostatinergic neurotransmission with FK960 in Alzheimer's disease.
Doggrell SA
Expert Opin Investig Drugs; 2004 Jan; 13(1):69-72. PubMed ID: 14680454
[TBL] [Abstract][Full Text] [Related]
2. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, restores the regional cerebral blood flow response abolished by scopolamine but not by HA-966: a positron emission tomography study with unanesthetized rhesus monkeys.
Tsukada H; Yamazaki S; Noda A; Inoue T; Matsuoka N; Kakiuchi T; Nishiyama S; Nishimura S
Brain Res; 1999 Jun; 832(1-2):118-23. PubMed ID: 10375657
[TBL] [Abstract][Full Text] [Related]
3. Measurement of brain concentration of FK960 for development of a novel antidementia drug: a PET study in conscious rhesus monkeys.
Noda A; Takamatsu H; Murakami Y; Yajima K; Tatsumi M; Ichise R; Nishimura S
J Nucl Med; 2003 Jan; 44(1):105-8. PubMed ID: 12515883
[TBL] [Abstract][Full Text] [Related]
4. Effect of N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960), an antidementia drug with a novel mechanism of action, on regional cerebral blood flow and glucose metabolism in aged rhesus macaques studied with positron emission tomography.
Noda A; Takamatsu H; Matsuoka N; Koyama S; Tsukada H; Nishimura S
J Pharmacol Exp Ther; 2003 Jul; 306(1):213-7. PubMed ID: 12676883
[TBL] [Abstract][Full Text] [Related]
5. FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices.
Inoue T; Wang F; Moriguchi A; Shirakawa K; Matsuoka N; Goto T
Brain Res; 2001 Feb; 892(1):111-7. PubMed ID: 11172755
[TBL] [Abstract][Full Text] [Related]
6. FK960 [N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate], a novel potential antidementia drug, improves visual recognition memory in rhesus monkeys: comparison with physostigmine.
Matsuoka N; Aigner TG
J Pharmacol Exp Ther; 1997 Mar; 280(3):1201-9. PubMed ID: 9067304
[TBL] [Abstract][Full Text] [Related]
7. FK960 N-(4-acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate ameliorates the memory deficits in rats through a novel mechanism of action.
Yamazaki M; Matsuoka N; Maeda N; Ohkubo Y; Yamaguchi I
J Pharmacol Exp Ther; 1996 Dec; 279(3):1157-73. PubMed ID: 8968337
[TBL] [Abstract][Full Text] [Related]
8. FK960, a novel potential anti-dementia drug, augments long-term potentiation in mossy fiber-CA3 pathway of guinea-pig hippocampal slices.
Matsuoka N; Satoh M
Brain Res; 1998 Jun; 794(2):248-54. PubMed ID: 9622644
[TBL] [Abstract][Full Text] [Related]
9. FK960, a potential anti-dementia drug, increases synaptic density in the hippocampal CA3 region of aged rats.
Moriguchi A; Nakano K; Yamaguchi I; Sano K; Noda K; Hashimoto M; Ohara K; Matsuoka N; Goto T
Brain Res; 2002 Dec; 958(2):381-9. PubMed ID: 12470874
[TBL] [Abstract][Full Text] [Related]
10. Combination of a novel antidementia drug FK960 with donepezil synergistically improves memory deficits in rats.
Tokita K; Yamazaki S; Yamazaki M; Matsuoka N; Mutoh S
Pharmacol Biochem Behav; 2002 Oct; 73(3):511-9. PubMed ID: 12151024
[TBL] [Abstract][Full Text] [Related]
11. Modulation of Ca2+ channel currents by a novel antidementia drug N-(4-Acetyl-1-piperazinyl)-p-fluorobenzamide monohydrate (FK960) in rat hippocampal neurons.
Wang F; Matsuoka N; Mutoh S; Kaneko S
J Pharmacol Exp Ther; 2004 Jan; 308(1):120-6. PubMed ID: 14569070
[TBL] [Abstract][Full Text] [Related]
12. Effect of FK960, a putative cognitive enhancer, on synaptic transmission in CA1 neurons of rat hippocampus.
Hodgkiss JP; Kelly JS
J Pharmacol Exp Ther; 2001 May; 297(2):620-8. PubMed ID: 11303051
[TBL] [Abstract][Full Text] [Related]
13. Sustained facilitatory action of FK960 on hippocampal neurotransmission.
Matsuyama S; Nomura T; Nishizaki T
Brain Res; 2000 Feb; 857(1-2):317-20. PubMed ID: 10700585
[TBL] [Abstract][Full Text] [Related]
14. Tadalafil crosses the blood-brain barrier and reverses cognitive dysfunction in a mouse model of AD.
García-Barroso C; Ricobaraza A; Pascual-Lucas M; Unceta N; Rico AJ; Goicolea MA; Sallés J; Lanciego JL; Oyarzabal J; Franco R; Cuadrado-Tejedor M; García-Osta A
Neuropharmacology; 2013 Jan; 64():114-23. PubMed ID: 22776546
[TBL] [Abstract][Full Text] [Related]
15. Altered cerebral vascular volumes and solute transport at the blood-brain barriers of two transgenic mouse models of Alzheimer's disease.
Do TM; Alata W; Dodacki A; Traversy MT; Chacun H; Pradier L; Scherrmann JM; Farinotti R; Calon F; Bourasset F
Neuropharmacology; 2014 Jun; 81():311-7. PubMed ID: 24631967
[TBL] [Abstract][Full Text] [Related]
16. The anti-dementia drug FK960 stimulates glial glutamate release via a PKA pathway.
Tada H; Uchino M; Nagai K; Nomura T; Kondoh T; Saito N; Yamamura T; Yajima Y; Nishizaki T
Brain Res Mol Brain Res; 2002 Dec; 109(1-2):63-8. PubMed ID: 12531516
[TBL] [Abstract][Full Text] [Related]
17. Sildenafil Improves Vascular and Metabolic Function in Patients with Alzheimer's Disease.
Sheng M; Lu H; Liu P; Li Y; Ravi H; Peng SL; Diaz-Arrastia R; Devous MD; Womack KB
J Alzheimers Dis; 2017; 60(4):1351-1364. PubMed ID: 29036811
[TBL] [Abstract][Full Text] [Related]
18. Cerebrovascular resistance: effects on cognitive decline, cortical atrophy, and progression to dementia.
Yew B; Nation DA;
Brain; 2017 Jul; 140(7):1987-2001. PubMed ID: 28575149
[TBL] [Abstract][Full Text] [Related]
19. Role of glial glutamate transporters in the facilitatory action of FK960 on hippocampal neurotransmission.
Tozaki H; Kanno T; Nomura T; Kondoh T; Kodama N; Saito N; Aihara H; Nagata T; Matsumoto S; Ohta K; Nagai K; Yajima Y; Nishizaki T
Brain Res Mol Brain Res; 2001 Dec; 97(1):7-12. PubMed ID: 11744157
[TBL] [Abstract][Full Text] [Related]
20. Changes in regional cerebral blood flow associated with a 45 day course of the ketogenic agent, caprylidene, in patients with mild to moderate Alzheimer's disease: Results of a randomized, double-blinded, pilot study.
Torosyan N; Sethanandha C; Grill JD; Dilley ML; Lee J; Cummings JL; Ossinalde C; Silverman DH
Exp Gerontol; 2018 Oct; 111():118-121. PubMed ID: 30006299
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
